MYC and cancer: Given that DJ34 has potent anti-c-Myc activity in a broad range of cancers, that it can simultaneously activate p53, and that LSCs are particularly sensitive to DJ34, we believe it forms an excellent starting point for further development of anti-c-Myc cancer therapy.